CureVac N.V. (5CV.F)

3,7420 +0,2560 (+7,34%) A partir del 10:11AM CEST. Mercado abierto.

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 999

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Alexander Zehnder M.B.A., M.D.	CEO, MD & Member of Management Board	978,33k	N/A	1970
Mr. Pierre Kemula B.Sc.	MD, CFO & Member of Management Board	654,17k	N/A	1975
Dr. Malte Greune Ph.D.	COO, Member of Management Board & MD	600,74k	N/A	1965
Dr. Myriam Mendila M.D.	Chief Scientific Officer, Head of R&D, MD & Member of the Management Board	614,49k	N/A	1966
Dr. Ulrike Gnad-Vogt M.D., Ph.D.	Senior VP & Area Head of Oncology	284,14k	N/A	1973
Dr. Sarah Fakih	Vice President Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Marco Rau L.L.M., Ph.D.	General Counsel	N/A	N/A	N/A
Mr. Thorsten Schuller	Head of Corporate Communications	N/A	N/A	N/A
Slavica Stevanovic-Heck	Head of Human Resources	N/A	N/A	N/A
Dr. Patrick Baumhof	Senior Vice President of Technology	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Gobierno corporativo

El ISS Governance QualityScore de CureVac N.V., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.